Information Provided By:
Fly News Breaks for February 27, 2019
RDHL
Feb 27, 2019 | 07:27 EDT
H.C. Wainwright analyst Swayampakula Ramakanth lowered his price target for RedHill Biopharma to $16 saying reliance on a potential partnership could reduce RHB-104's economic value. Based on management comments, the analyst believes RedHill will likely wait for a partnership before moving the RHB-104 program forward. However, Ramakanth still expects Talicia to be approved with a potential commercial launch in the U.S. by Q4. The analyst reiterates a Buy rating on the shares.
News For RDHL From the Last 2 Days
There are no results for your query RDHL
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.